The Pennine Acute Hospitals Formulary

	The Pennine Acute Hospitals
	NHS Trust Formulary

Search

Formulary Chapter 13: Skin - Full Chapter

Notes:

Dermatology services are provided by visiting consultants from Salford Royal Foundation Trust, and choice of therapy is therefore guided by SRFT's formulary. To confirm the formulary status of a product, please see http://www.srft.nhs.uk/for-professionals/formulary/

Details...

13.04

Topical corticosteroids

Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 3% (Diprosalic^®)
(Potency: Potent)

Formulary

Ointment
Scalp Application

Betamethasone (as Valerate) 0.025% (Betnovate-RD^®)
(Potency: Moderate)

Formulary

Cream
Ointment

Betamethasone (as Valerate) 0.1% (Betnovate Scalp^®)
(Potency: Potent)

Formulary

Scalp application

Betamethasone (as Valerate) 0.1% (Non-proprietary or Betnovate^®)
(Potency: Potent)

Formulary

Cream
Ointment

Betamethasone Valerate 0.1% Scalp Application (Betacap^®)
(Potency: Potent)

Formulary

Scalp application

Clobetasol Propionate 0.05% (Dermovate^®)
(Potency: Very Potent)

Formulary

Cream
Ointment
Scalp Application

Clobetasol Propionate 0.05% (Etrivex^®)
(Potency: Very Potent)

Restricted

Shampoo

Dermatology only

Clobetasone Butyrate 0.05% (Eumovate^®)
(Potency: Moderate)

Formulary

Cream
Ointment

Fludroxycortide (Haelan^®)
(Potency: Moderate)

Formulary

Cream
Ointment
Tape (for chronic localised recalcitrant dermatoses, but not acute or weeping)

Fluocinolone Acetonide 0.0025% (Synalar 1 in 10 Dilution^®)
(Potency: Mild)

Formulary

Cream

Fluocinolone Acetonide 0.00625% (Synalar 1 in 4 Dilution^®)
(Potency: Moderate)

Formulary

Cream
Ointment

Fluocinolone Acetonide 0.025% (Synalar^®)
(Potency: Potent)

Formulary

Cream
Gel
Ointment

Fluocinonide 0.05% (Metosyn^®)

Restricted

FAPG cream

Dermatology only

Hydrocortisone
(Potency: Mild)

Formulary

Cream (0.5%, 1%, 2.5%)
Ointment (0.5%, 1%, 2.5%)

Hydrocortisone 1%, Urea 10% and Lactic Acid 5% (Calmurid HC^®)
(Potency: Moderate)

Formulary

Cream

Hydrocortisone Butyrate 0.1% (Locoid^®)
(Potency: Potent)

Formulary

Cream
Ointment

Mometasone Furoate 0.1% (Non-proprietary or Elocon^®)
(Potency: Potent)

Restricted

Cream
Ointment

Dermatology only

NICE TA81: Atopic dermatitis (eczema) - topical steroids

UKMI Q&A: Can topical steroids be applied at the same time as emollients?

13.04

With antimicrobials

Betamethasone (as Valerate) 0.1% with Clioquinol (Non proprietary or Betnovate-C^®)
(Potency: Potent)

Formulary

Cream
Ointment

Betamethasone (as Valerate) 0.1% with Fucidic Acid 2% (Fucibet^®)
(Potency: Potent)

Formulary

Cream

Betamethasone (as Valerate) 0.1% with Neomycin Sulphate 0.5% (Non-proprietary or Betnovate-N^®)
(Potency: Potent)

Formulary

Cream
Ointment

Betamethasone Dipropionate 0.064% with Clotrimazole 1% (Lotriderm^®)
(Potency: Potent)

Formulary

Cream

Clobetasone butyrate 0.05% with Oxytetracycline and Nystatin (Trimovate^®)
(Potency: Moderate)

Formulary

Cream

Fluocinolone Acetonide 0.025% with Clioquinol 3% (Synalar C^®)
(Potency: Potent)

Formulary

Cream
Ointment

Fluocinolone Acetonide 0.025% with Neomycin Sulphate 0.5% (Synalar N^®)
(Potency: Potent)

Formulary

Cream
Ointment

Hydrocortisone 0.5% with Nystatin and Chlorhexidine (Nystaform-HC^®)
(Potency: Mild)

Formulary

Cream
Ointment

Hydrocortisone 0.5% with Nystatin, Benzalkonium and Dimeticone (Timodine^®)
(Potency: Mild)

Formulary

Cream

Hydrocortisone 1% with Clotrimazole 1% (Canesten HC^®)
(Potency: Mild)

Formulary

Cream

Hydrocortisone 1% with Miconazole Nitrate 2% (Daktacort^®)
(Potency: Mild)

Formulary

Cream
Ointment

MHRA Safety Alert: serious interactions between topical miconazole and warfarin

Hydrocortisone Acetate 1% with Fusidic Acid 2% (Fucidin H^®)
(Potency: Mild)

Formulary

Cream

Triamcinolone Acetonide 0.1% with Chlortetracycline Hydrochloride 3% (Aureocort^®)
(Potency: Potent)

Formulary

Ointment

....

Non Formulary Items

Alclometasone Dipopionate (Modrasone^®)

Non Formulary

Beclometasone Dipropionate 0.025%

Non Formulary

Betamethasone (as Dipropionate) 0.05% (Diprosone^®)

Non Formulary

Betamethasone Esters (Betesil^®)

Non Formulary

Betamethasone valerate 0.12% (Bettamousse^®)

Non Formulary

Clobetasol propionate (Clarelux^®)

Non Formulary

Clobetasol Propionate with Neomycin and Nystatin

Non Formulary

Diflucortolone Valerate (Nerisone Forte^®)

Non Formulary

Diflucortolone Valerate 0.1% (Nerisone^®)

Non Formulary

Doxepin Hydrochloride (Xepin^®)

Non Formulary

Fluocortolone (Ultralanum Plain^®)

Non Formulary

Fluticasone Propionate (Cutivate^®)

Non Formulary

Hydrocortisone (Dioderm^®)
(0.1%)

Non Formulary

Hydrocortisone (Efcortelan^®)

Non Formulary

Hydrocortisone (Hydromol^® HC Intensive)

Non Formulary

Hydrocortisone (Mildison^®)

Non Formulary

Hydrocortisone 0.25% Crotamiton 10% (Eurax-Hydrocortisone^®)

Non Formulary

DISCONTINUED

Hydrocortisone 1% with Urea 10% (Alphaderm^®)

Non Formulary

Hydrocortisone 1%, Clioquinol 3% (Vioform-Hydrocortisone^®)

Non Formulary

Hydrocortisone Acetate 1% with Oxytetracycline 3% (Terra-Cortril^®)

Non Formulary

Hydrocortisone Butyrate (Locoid Crelo^®)

Non Formulary

Hydrocortisone Butyrate 0.1% with Chlorquinaldol 3% (Locoid C^®)

Non Formulary

DISCONTINUED

Hydrocortisone with antimicrobials (Econacort^®)

Non Formulary

Tri-Adcortyl^®

Non Formulary

Key

	Notes
	Section Title (top level)
	Section Title (sub level)
	First Choice item
	Non Formulary section
	Restricted Drug
	Unlicensed
	Display tracking information
	Link to adult BNF
	Link to children's BNF
	Link to SPCs
	Scottish Medicines Consortium

	Cytotoxic Drug
	Controlled Drug
	High Cost Medicine
	Cancer Drugs Fund
	NHS England
	Homecare
	CCG

Traffic Light Status Information

Status	Description
	Drugs designated amber are suitable for shared care arrangements under a shared care protocol. Prescribing may be transferred from secondary to primary care once the patient is stabilised and agreed shared care arrangements have been established. Alternatively primary care may initiate under the supervision of secondary care if this option is given in the shared care document. It is recommended that shared care arrangements should be drawn up following local discussion and agreement by prescribing parties.
	These products have been reviewed by the GM Joint Formulary Group and have been deemed not suitable for prescribing for adults in primary or secondary care within Greater Manchester. These decisions have been made on the basis of safety, efficacy and cost-effectiveness of the products.
	Not used
	Drugs designated green1 are suitable for initiation and ongoing prescribing within primary care.
	Drugs designated green2 can be initiated by primary care following written or verbal advice from a specialist and then be subsequently safely prescribed in primary care with little or no monitoring required.
	Drugs designated green3 are suitable for on-going prescribing within primary care after specialist initiation and an initial review (unless specified) in secondary care. Little or no monitoring is required.
	Not suitable for routine prescribing but may be suitable for a defined patient population. Whilst prescribers should think very carefully before prescribing or recommending any of the products on the grey list, there may be exceptional instances when the use of one of these products is necessary for a particular patient.
	Drugs designated red are considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy, this may include arranging for supply via a home care company.